ATE161411T1 - Vorrichtung zur transdermalen verabreichung von arzneimitteln mit einer kontrollierten, zeitlichen strömungsänderung - Google Patents

Vorrichtung zur transdermalen verabreichung von arzneimitteln mit einer kontrollierten, zeitlichen strömungsänderung

Info

Publication number
ATE161411T1
ATE161411T1 AT92922512T AT92922512T ATE161411T1 AT E161411 T1 ATE161411 T1 AT E161411T1 AT 92922512 T AT92922512 T AT 92922512T AT 92922512 T AT92922512 T AT 92922512T AT E161411 T1 ATE161411 T1 AT E161411T1
Authority
AT
Austria
Prior art keywords
pct
drug
volatile
permeation enhancer
backing
Prior art date
Application number
AT92922512T
Other languages
English (en)
Inventor
Renee A Fallon
Donald R Wilson
Russell D Beste
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Application granted granted Critical
Publication of ATE161411T1 publication Critical patent/ATE161411T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00553—Plasters form or structure with detachable parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00604—Multilayer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00646—Medication patches, e.g. transcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Printing Plates And Materials Therefor (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92922512T 1991-10-10 1992-10-09 Vorrichtung zur transdermalen verabreichung von arzneimitteln mit einer kontrollierten, zeitlichen strömungsänderung ATE161411T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/775,638 US5352456A (en) 1991-10-10 1991-10-10 Device for administering drug transdermally which provides an initial pulse of drug

Publications (1)

Publication Number Publication Date
ATE161411T1 true ATE161411T1 (de) 1998-01-15

Family

ID=25105020

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92922512T ATE161411T1 (de) 1991-10-10 1992-10-09 Vorrichtung zur transdermalen verabreichung von arzneimitteln mit einer kontrollierten, zeitlichen strömungsänderung

Country Status (10)

Country Link
US (2) US5352456A (de)
EP (1) EP0608357B1 (de)
JP (1) JP3011459B2 (de)
AT (1) ATE161411T1 (de)
AU (1) AU657582B2 (de)
CA (1) CA2120508A1 (de)
DE (1) DE69223801T2 (de)
FI (1) FI941569A7 (de)
NO (1) NO308395B1 (de)
WO (1) WO1993006803A1 (de)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352456A (en) * 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
FR2735027B1 (fr) * 1995-06-07 1998-01-09 Alza Corp Compositions de renforcateurs de permeation d'agents a travers la peau, comprenant de l'acetate de lauryle et un monoglyceride
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US20020114827A1 (en) * 1995-07-28 2002-08-22 Jie Zhang Methods and apparatus for improved administration of analgesics
US20040265353A1 (en) * 1995-07-28 2004-12-30 Zars, Inc. Systems and methods for treating panic attacks
DE19546024C2 (de) * 1995-12-09 1998-09-10 Lohmann Therapie Syst Lts Transdermale pharmazeutische Zubereitung und deren Herstellung
US5686096A (en) * 1995-12-22 1997-11-11 Becton Dickinson And Company Medical device for the protection of a catheter penetration site
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
AU758193B2 (en) * 1996-09-17 2003-03-20 U.D. Testing, Inc. Therepeutic agent with quantitative consumption marker
AU736645B2 (en) * 1996-09-17 2001-08-02 U.D. Testing, Inc. Therapeutic agent with quantitative consumption marker and method of monitoring therapeutic agent consumption
US6660295B2 (en) 1997-09-30 2003-12-09 Alza Corporation Transdermal drug delivery device package with improved drug stability
WO1999032153A1 (en) 1997-12-22 1999-07-01 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
US5900249A (en) * 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
US6136801A (en) * 1998-12-24 2000-10-24 U. D. Testing, Inc. Therapeutic agent with quantitative consumption marker
KR20010036685A (ko) 1999-10-11 2001-05-07 김윤 펜타닐을 함유하는 매트릭스형 경피투여제
WO2001064149A1 (en) * 2000-02-29 2001-09-07 Jie Zhang Improved transdermal drug patch
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
DE10102817B4 (de) * 2001-01-23 2006-01-12 Lts Lohmann Therapie-Systeme Ag Vorrichtung und Verfahren zur Hitzepulsgestützten transdermalen Applikation von Wirkstoffen
US20030118653A1 (en) * 2001-07-06 2003-06-26 Lavipharm Laboratories Inc. Quick dissolving oral mucosal drug delivery device with moisture barrier coating
CA2460352C (en) * 2001-08-17 2013-05-14 Lavipharm Laboratories Inc. Composition and transdermal drug delivery device
KR100844312B1 (ko) * 2001-09-06 2008-07-07 노사케미컬(주) 펜타닐 경피 투여 제제
DK1469723T3 (da) * 2002-01-31 2007-03-05 Disease Control Textiles Sa Lamineret insekticiddoseringsorgan
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2492654A1 (en) * 2002-07-16 2004-01-22 University Of South Florida Human immunosuppressive protein
EP2316459B1 (de) 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidindiaminen zur Behandlung oder Vorbeugung von Autoimmunerkrankungen
CN100336569C (zh) * 2002-10-20 2007-09-12 浙江大学 经皮给药电穿孔系统
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
JP2006510618A (ja) 2002-11-18 2006-03-30 ヤウポン セラピューティクス，インコーポレーテッド ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
WO2004075933A2 (en) * 2003-02-26 2004-09-10 Lavipharm S.A. Devices for releasing volatile substances and methods of producing the devices
WO2004094457A2 (en) * 2003-04-16 2004-11-04 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Stable rgd peptidomimetic composition
ATE506953T1 (de) 2003-08-07 2011-05-15 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
ATE448828T1 (de) * 2003-10-27 2009-12-15 Univ Basel Transdermales arzneimittelabgabesystem
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2005284908B2 (en) * 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
ES2527340T3 (es) 2005-05-24 2015-01-22 Chrono Therapeutics, Inc. Dispositivo portátil de administración de fármaco que incluye un elemento de dosificación o administración desmontable y reemplazable
WO2006127905A2 (en) * 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
WO2007092350A1 (en) * 2006-02-02 2007-08-16 H.B. Fuller Licensing & Financing, Inc. Wound care articles, drug delivery systems and methods of using the same
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US9109204B2 (en) 2006-02-28 2015-08-18 The Trustees Of Columbia University In The City Of New York Methods for compact aggregation of dermal cells
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
WO2008008281A2 (en) 2006-07-07 2008-01-17 Proteus Biomedical, Inc. Smart parenteral administration system
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
ATE540041T1 (de) 2006-11-21 2012-01-15 Rigel Pharmaceuticals Inc Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
US7820207B2 (en) * 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
US8034983B2 (en) * 2007-06-06 2011-10-11 Multi-Tech Specialty Chemicals, Co., Ltd. Process for the preparation of xanthophyll crystals
JP2010530902A (ja) * 2007-06-22 2010-09-16 サイエル ファーマ，インコーポレイティド 流涎症治療のためのグリコピロレートを含む経皮送達システム
WO2009055733A1 (en) 2007-10-25 2009-04-30 Proteus Biomedical, Inc. Fluid transfer port information system
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
RS54413B1 (sr) * 2008-08-22 2016-04-28 Sanofi [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
JP5815411B2 (ja) 2008-12-30 2015-11-17 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジンジアミンキナーゼ阻害剤
BRPI1006942A2 (pt) 2009-01-23 2016-04-12 Rigel Pharmaceuticals Inc composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto
EP2393488B1 (de) 2009-02-06 2019-06-19 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
AU2010270797B2 (en) 2009-07-08 2015-03-19 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US20110034415A1 (en) 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
WO2011053468A1 (en) 2009-10-30 2011-05-05 Sanofi-Aventis Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
RS53456B (sr) 2009-12-23 2014-12-31 Sanofi Prolekovi [4[4-(5-aminometil-2-fluor-fenil)-piperidin-1-il]-(1h-pirolo-piridin-il)-metanona i njihova sinteza
CA2785439A1 (en) 2009-12-23 2011-06-30 Sanofi [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
SG189763A1 (en) 2010-02-01 2013-05-31 Proteus Digital Health Inc Two-wrist data gathering system
EP2531099B1 (de) 2010-02-01 2018-12-12 Proteus Digital Health, Inc. Datensammelsystem
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
CN103096889A (zh) 2010-04-20 2013-05-08 寰宇一家健康研究所 包含1,3,4-噁二唑衍生物的化合物、组合物和方法
US20110288093A1 (en) 2010-04-20 2011-11-24 Institute For Oneworld Health Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives
AU2011242562B2 (en) 2010-04-24 2016-10-13 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
JP6073221B2 (ja) 2010-07-28 2017-02-01 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
US9056855B2 (en) 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
KR101848077B1 (ko) 2010-11-13 2018-04-11 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
CN103328452A (zh) 2010-12-13 2013-09-25 威尔金制药有限公司 金属酶抑制剂化合物
CA2828360A1 (en) 2011-02-25 2012-08-30 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Chrysophaentin analogs that inhibit ftsz protein
CN103501821A (zh) 2011-03-08 2014-01-08 艾克塞斯制药公司 用于递送活性剂穿过生物膜的靶向纳米载体系统
AU2012273100B2 (en) 2011-06-19 2017-05-25 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
KR20140040235A (ko) 2011-06-19 2014-04-02 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
US8940735B2 (en) 2011-06-23 2015-01-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
CN103930165B (zh) 2011-09-02 2018-05-25 纽约市哥伦比亚大学理事会 用以治疗肥胖症的代谢紊乱的CaMKII、IP3R、钙调神经磷酸酶、P38和MK2/3抑制剂
IN2014MN01378A (de) 2011-12-11 2015-07-03 Viamet Pharmaceuticals Inc
WO2013109998A1 (en) 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2865504A1 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
JP2016506930A (ja) 2013-01-25 2016-03-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患を処置するための化合物および方法
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
EP2968551B1 (de) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusionsproteine und verfahren dafür
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
US9974754B2 (en) 2013-12-18 2018-05-22 Maruishi Pharmaceutical Co., Ltd. Hydrous adhesive patch
MX2016011517A (es) 2014-03-07 2017-04-13 Univ Arizona Peptidos de crmp2 no narcoticos que seleccionan como diana canales de sodio para el dolor cronico.
WO2015143184A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3925979A3 (de) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusionsproteine und verfahren dafür
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
KR102603277B1 (ko) 2015-03-19 2023-11-17 마이코비아 파마슈티컬즈, 인코포레이티드 항진균성 화합물 및 이의 제조 방법
DK3331879T3 (da) 2015-08-04 2020-08-10 Rigel Pharmaceuticals Inc Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
CN108289457B (zh) 2015-09-18 2021-08-06 迈科维亚医药公司 抗真菌化合物制备方法
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
EA038421B1 (ru) 2015-12-30 2021-08-26 ВиПиЭс-3, ИНК. Соединения, ингибирующие металлоферменты
EP3434267B1 (de) 2016-03-24 2023-07-26 MEDRx Co., Ltd. Pflasterzubereitung mit eigenschaften zur verhinderung von missbrauch
WO2017210611A1 (en) 2016-06-03 2017-12-07 Biovinc, Llc. Bisphosphonate quinolone conjugates and uses thereof
EP3475263B1 (de) 2016-06-27 2022-12-28 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidinverbindungen und dessen verwendung als irak4 hemmer
ES2985944T3 (es) 2016-06-29 2024-11-07 Halo Life Science Llc Método de preparación de una sal de ellagato de dicolinio de poco olor y otras sales orgánicas de colina de poco olor
JP7170634B2 (ja) 2016-10-26 2022-11-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｉｒａｋ阻害剤としての使用のためのオキサゾール誘導体およびその調製のための方法
ES2946001T3 (es) 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
EP3562306B1 (de) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzym-inhibitor-verbindungen
JP7227157B2 (ja) 2016-12-29 2023-02-21 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3068305A1 (en) 2017-06-29 2019-01-03 Rigel Pharmaceuticals, Inc. Kinase inhibitors and methods for making and using
MD3788045T2 (ro) 2018-05-03 2023-09-30 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
HRP20231381T1 (hr) 2018-05-03 2024-03-01 Rigel Pharmaceuticals, Inc. Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
CA3105829A1 (en) 2018-07-09 2020-01-16 Biovinc, Llc. Bisphosphonate quinolone conjugates and uses thereof
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
JP2022516969A (ja) 2019-01-08 2022-03-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
TWI772807B (zh) 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 外用製劑
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
MX2022001596A (es) 2019-08-08 2022-03-11 Rigel Pharmaceuticals Inc Compuestos y metodos para tratar sindrome de liberacion de citocinas.
EP4013420B1 (de) 2019-08-14 2023-11-01 Rigel Pharmaceuticals, Inc. Verfahren zur blockierung oder linderung des zytokinfreisetzungssyndroms
PE20220970A1 (es) 2019-08-30 2022-06-10 Rigel Pharmaceuticals Inc Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones
JP7493586B2 (ja) 2019-09-06 2024-05-31 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
CA3149926A1 (en) 2019-09-06 2021-03-11 Yan Chen Rip1 inhibitory compounds and methods for making and using the same
SI4055021T1 (sl) 2019-11-07 2026-02-27 Rigel Pharmaceuticals, Inc. Heterociklične spojine, ki inhibirajo rip1
US12357623B2 (en) 2021-03-03 2025-07-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
IL315677A (en) 2022-03-23 2024-11-01 Rigel Pharmaceuticals Inc Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4698062A (en) * 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
US4927632A (en) * 1986-06-26 1990-05-22 Alza Corporation Selective pulsed drug delivery system
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US4956181A (en) * 1987-05-08 1990-09-11 Eastman Kodak Nitrate therapy for angina pectoris
US4764379A (en) * 1987-08-24 1988-08-16 Alza Corporation Transdermal drug delivery device with dual permeation enhancers
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5300291A (en) * 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US4814168A (en) * 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US5352456A (en) * 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug

Also Published As

Publication number Publication date
US5820875A (en) 1998-10-13
NO941255D0 (no) 1994-04-07
EP0608357B1 (de) 1997-12-29
JP3011459B2 (ja) 2000-02-21
NO941255L (no) 1994-04-07
FI941569L (fi) 1994-06-06
FI941569A0 (fi) 1994-04-06
EP0608357A1 (de) 1994-08-03
AU657582B2 (en) 1995-03-16
FI941569A7 (fi) 1994-06-06
DE69223801T2 (de) 1998-07-30
DE69223801D1 (de) 1998-02-05
AU2796192A (en) 1993-05-03
EP0608357A4 (en) 1994-08-17
CA2120508A1 (en) 1993-04-15
JPH07504882A (ja) 1995-06-01
WO1993006803A1 (en) 1993-04-15
US5352456A (en) 1994-10-04
NO308395B1 (no) 2000-09-11

Similar Documents

Publication Publication Date Title
ATE161411T1 (de) Vorrichtung zur transdermalen verabreichung von arzneimitteln mit einer kontrollierten, zeitlichen strömungsänderung
KR890003413A (ko) 이중 침투증대제를 가진 경피식 약물투여장치
ATE142115T1 (de) Hautelektrodenaufbau und dazugehöriges gerät zur transdermalen verabreichung von heilmitteln
ATE5563T1 (de) Therapeutisches system zum zufuehren von arzneimitteln zur haut.
NZ313984A (en) Transcorneal drug-release system with multiple microblades and pump
ATE215363T1 (de) Estradiol-penetrationsverstärker zur transdermalen verabreichung
DE69220808D1 (de) Vorrichtung zur verabreichung von heilmitteln
DE19681435T1 (de) Neue Formulierungen zur transdermalen Abgabe von Pergolid
HU9802889D0 (en) Percutaneous absorption type preparation
DE69326848D1 (de) Oxybutynin zur transdermalen Verabreichung
ATE63059T1 (de) Vorrichtung mit zwei schichten zur freisetzung von arzneimitteln.
FI95539C (fi) Transdermaalinen järjestelmä, sen valmistusmenetelmä ja käyttö
DK166193C (da) Plaster med aktivstof til kontrolleret administration af aktivstoffer til huden
PT93191A (pt) Sistema terapeutico para a administracao retardada e controlada transdermica ou transmucosica de substancias activas
ATE163854T1 (de) Dexpanthenol-haltiges pflaster zur transdermalen applikation von steroidhormonen
GR960100177A (el) Συσκευη διαδερμικης χορηγησης των φεντανιλ και σουφεντανιλ με ηλεκτρομεταφορα.
ATE447398T1 (de) Durchsichtige transdermale nicotinabgabevorrichtungen
ES2043744T3 (es) Sistema de suministro transdermico de procaterol.
DE58909724D1 (de) Verwendung einer Vorrichtung mit einem Wirkstoffreservoir für gesteuerte Wirkstoffabgabe
ATE204765T1 (de) Transdermales therapeutisches system mit druckfarbenfreier identifikation und verfahren zu seiner herstellung
ATE185069T1 (de) Flächenstabilisierte pharmazeutische zubereitung zur anwendung auf der haut
LV10749A (lv) Transdermala terapeitiska sistema fizostigmina uzliksanai uz adas un tas izgatavosanas panemiens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties